Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 392 participants.

Also called NCT05238012

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 392 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as a collaborator
Registry
  • NCT NCT05238012
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05238012. Randomized; no masking; primary purpose treatment. Start 2022-08-02 (actual); primary completion 2024-04-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
Acronym
XTREME
Condition
Metabolism Disorder, Lipid
Condition
Metabolism Disorder, Glucose
Intervention (Drug)
Xuezhikang Capsule
Intervention (Drug)
Atorvastatin Calcium Tablets
Lead sponsor
Heart Health Research Center (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct05238012
Content hash
e50d633c0118908e4c343caa1753fa0e2cfebec581b93bebf5345be036874e3a